Nonglycemic effects of incretins in patients with long-term type 1 diabetes mellitus and chronic kidney disease

Nonglycemic effects of incretins in patients with long-term type 1 diabetes mellitus and chronic kidney disease

Aim. To investigate the nonglycemic effects of incretins in patients with type 1 diabetes mellitus (DM1) of long duration (for more than 20 years) and chronic kidney disease. Subjects and methods. Seventy-five patients with varying degrees of diabetic nephropathy (DN) and without this condition, inc...

Full description

Bibliographic Details
Main Authors:	M S Arutyunova, A M Glazunova, O V Mikhaleva, Z T Zuraeva, S A Martynov, I I Klefortova, O V Manchenko, I N Ulyanova, A V Ilyin, M Sh Shamkhalova, M V Shestakova
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2015-10-01
Series:	Терапевтический архив
Subjects:	type 1 diabetes mellitus glucagon-like peptide-1 glucose-dependent insulinotropic peptide chronic kidney disease
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/31827

Similar Items

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
by: Stanchev Pavel E., et al.
Published: (2019-03-01)

The Change in Glucagon Following Meal Ingestion Is Associated with Glycemic Control, but Not with Incretin, in People with Diabetes
by: Soyeon Yoo, et al.
Published: (2021-06-01)

Effects of passage through the digestive tract on incretin secretion: Before and after birth
by: Seiichi Tomotaki, et al.
Published: (2021-06-01)

Incretin secretion and glucose metabolism in morbidly obese patients in the early and late periods after biliopancreatic diversion
by: I I Dedov, et al.
Published: (2016-10-01)

Effects of passage through the digestive tract on incretin secretion: Before and after birth
by: Tomotaki, Seiichi
Published: (2021)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Insulin and incretin responses to grazing in insulin‐dysregulated and healthy ponies
by: Danielle M. Fitzgerald, et al.
Published: (2019-01-01)

A pilot study of the efficacy of miglitol and sitagliptin for type 2diabetes with a continuous glucose monitoring system and incretin-related markers
by: Kishimoto Miyako, et al.
Published: (2011-12-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-04-01)

Glycemic and Metabolic Effects of Two Long Bouts of Moderate-Intensity Exercise in Men with Normal Glucose Tolerance or Type 2 Diabetes
by: Saeed Reza Eshghi, et al.
Published: (2017-07-01)

Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury
by: Miaad Bader, et al.
Published: (2020-01-01)

Common variants in the hERG (KCNH2) voltage-gated potassium channel are associated with altered fasting and glucose-stimulated plasma incretin and glucagon responses
by: Line Engelbrechtsen, et al.
Published: (2018-03-01)

The Impact of a Large Bolus Dose of <span style="font-variant: small-caps">l</span>-leucine and <span style="font-variant: small-caps">l</span>-isoleucine on Enteroendocrine and Pancreatic Hormones, and Glycemia in Healthy, Inactive Adults
by: Daniel E. Newmire, et al.
Published: (2019-11-01)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-04-01)

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
by: Jared Rosenberg, et al.
Published: (2021-09-01)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
by: David S. Mathiesen, et al.
Published: (2019-08-01)

DOES PALM MID FRACTION AFFECT ADULT SATIETY?
by: Lee, V.K.M, et al.
Published: (2021)

Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract
by: Nadya M. Morrow, et al.
Published: (2021-09-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

Renal experiences of bariatric surgery in patients with type 2 diabetes mellitus
by: I I Larina, et al.
Published: (2018-10-01)

Pleiotropic effects of incretins
by: Vishal Gupta
Published: (2012-01-01)

Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-09-01)

The Postprandial Glycaemic and Hormonal Responses Following the Ingestion of a Novel, Ready-to-Drink Shot Containing a Low Dose of Whey Protein in Centrally Obese and Lean Adult Males: A Randomised Controlled Trial
by: Kieran Smith, et al.
Published: (2021-06-01)

Understanding the Cardiovascular Effects of Incretin
by: Ji Sung Yoon, et al.
Published: (2011-10-01)

Incretin dysregulation of lysyl oxidase: a novel mechanism for diabetic osteopenia
by: Daley, Eileen
Published: (2019)

Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
by: O K Vikulova, et al.
Published: (2018-06-01)

A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide-expressing cells in the hypothalamus
by: Adriaenssens, A., et al.
Published: (2022)

Stress hyperglycaemia in critically ill patients: Potential role of incretin hormones; a preliminary study Hiperglucemia de estrés en el paciente crítico: papel potencial de las incretinas; estudio preliminar
by: J. A. Llompart-Pou, et al.
Published: (2012-02-01)

Consequences on islet and incretin hormone responses to dinner by omission of lunch in healthy men
by: Ola Lindgren, et al.
Published: (2020-07-01)

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
by: Shu-Chen Lu, et al.
Published: (2021-05-01)

Potential for Gut Peptide-Based Therapy in Postprandial Hypotension
by: Malcolm J. Borg, et al.
Published: (2021-08-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-10-01)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
by: Awadhesh Kumar Singh
Published: (2015-01-01)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
by: Knop FK, et al.
Published: (2010-05-01)

Role of Incretin Axis in Inflammatory Bowel Disease
by: Lihua Duan, et al.
Published: (2017-12-01)

Incretin-based therapy: renal effects
by: Anton Ivanovich Korbut, et al.
Published: (2016-01-01)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
by: Jonas Ronn, et al.
Published: (2017-12-01)

The emerging role of incretins in the pathophysiology of insulin resistance in type 1 diabetes.
by: Gorana Mirošević, et al.
Published: (2017-09-01)